Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Lurtotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 19/20 | 0.98 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lurtotecan SCHEMBL1649335 | 1.00 | TOP1 (0.98) | TOP1SLC2A1 | |
| Lurtotecan SCHEMBL13992 | 0.99 | TOP1 (1.00) | TOP1SLC2A1 | |
| Lurtotecan SCHEMBL29774186 | 0.99 | TOP1 (1.00) | TOP1SLC2A1 | |
| Lurtotecan SCHEMBL19208 | 0.99 | TOP1 (1.00) | TOP1SLC2A1 | |
| Lurtotecan SCHEMBL1649336 | 0.98 | TOP1 (0.97) | TOP1SLC2A1 | |
| SCHEMBL21410041 | 0.95 | TOP1 (1.00) | TOP1SLC2A1 | |
| SCHEMBL21450469 | 0.95 | TOP1 (1.00) | TOP1SLC2A1 | |
| SCHEMBL31312371 | 0.95 | TOP1 (1.00) | TOP1SLC2A1 | |
| SCHEMBL15150090 | 0.92 | TOP1 (0.87) | TOP1SLC2A1 | |
| SCHEMBL17057475 | 0.92 | TOP1 (0.86) | TOP1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4531847-A2 | CANCER TREATMENT USING TOPOISOMERASE I INHIBITORS AND PLK1 INHIBITORS | Cardiff Oncology, Inc. (US) | 2025-04-09 | — | — | EP | claimed |
| CN-117500528-A | Linker and conjugate thereof | 北京海步医药科技有限公司 | 2024-02-02 | — | — | CN | claimed |
| WO-2023235716-A2 | CANCER TREATMENT USING TOPOISOMERASE I INHIBITORS AND PLK1 INHIBITORS | CARDIFF ONCOLOGY, INC. (US) | 2023-12-07 | — | — | WO | claimed |
| CN-110665009-B | Nanometer gemcitabine for promoting normalization of tumor blood vessels and application thereof | 中国药科大学 | 2023-03-14 | — | — | CN | claimed |
| US-20230023537-A1 | DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | LADRX CORPORATION | 2023-01-26 | — | — | US | claimed |
| WO-2022262516-A1 | LINKER AND CONJUGATE THEREFOR | 北京海步医药科技有限公司 | 2022-12-22 | — | — | WO | claimed |
| US-11384104-B2 | Delivery systems for controlled drug release | CENTURION BIOPHARMA CORPORATION (US) | 2022-07-12 | — | — | US | claimed |
| EP-4747302-A2 | REPAIR AND OPTIMIZATION OF NANOCOMPOSITE MATERIALS | Nanocore ApS (DK) | 2026-05-27 | — | — | EP | disclosed |
| US-RE50880-E1 | Anti-human OX40L antibodies and methods of treatment | KYMAB LIMITED (GB) | 2026-05-05 | — | — | US | disclosed |
| US-12616723-B1 | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity | BERMUDES DAVID GORDON (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4716554-A1 | PD-L1 AND TROP-2 TARGETING CONJUGATES COMPRISING EFFECTOR MOLECULES AND USES THEREOF | Allygen Group (KY) | 2026-04-01 | — | — | EP | disclosed |
| US-12582145-B2 | Aerial mycelia and methods of making same | ECOVATIVE LLC (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4705346-A2 | ANTI-CCR8 ANTIBODIES, CONJUGATES, AND USES THEREOF | Abilita Bio, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| CN-114230664-A | anti-C10 ORF54 antibodies and uses thereof | 皮埃尔法布雷医药公司 | 2022-03-25 | — | — | CN | disclosed |
| EP-3381943-B1 | ANTI-KIT ANTIBODIES AND USES THEREOF | CELLDEX THERAPEUTICS INC (US) | 2022-03-16 | — | — | EP | disclosed |
| WO-2022046888-A1 | SARS-COV-2 ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USE | Target Discovery Merger Sub II, LLC (US) | 2022-03-03 | — | — | WO | disclosed |
| US-11253590-B2 | Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator) | STSCIENCES, INC. (KR) | 2022-02-22 | — | — | US | disclosed |
| EP-3954394-A1 | DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | Centurion BioPharma Corporation (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-108064169-B | Antibodies, uses and methods | 科马布有限公司 | 2022-02-11 | — | — | CN | disclosed |
| US-20220031841-A1 | CANCER ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USE | Absci Corporation | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384104-B2 | Delivery systems for controlled drug release | ABCB11, SLC10A1, SLC5A1 | TOP1 1182/4885SLC2A1 50/4885 |
| US-12582145-B2 | Aerial mycelia and methods of making same | MYC, MYCBP, MYADM | TOP1 3457/4885SLC2A1 3299/4885 |
| US-20230023537-A1 | DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | ABCB11, SLC10A1, SLC5A1 | TOP1 1182/4885SLC2A1 50/4885 |
| US-12616723-B1 | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity | CD274, PDCD1, PDCD1LG2 | TOP1 499/4885SLC2A1 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.